Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFARI study of switching from aflibercept to ranibizumab in neovascular age-related macular degeneration
2014-001085-10Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in exudative macular degeneration, sponsored by Novartis. Started Jul 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2014-001085-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001085-10.